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Author statement
Revised Version of ‘The Importance of Post Neoadjuvant Histological 
Assessment and Need for Standardisation’ 
 
We would like to submit our revised review article entitled ‘The Importance of 
Post Neoadjuvant Histological Assessment and Need for Standardisation’ for 
your consideration. We thank the reviewers for their constructive comments, 
and are glad that they found the review interesting, stimulating and 
informative. 
 
In response to Reviewer 1’s comment: 
 
1. ‘Clips should be sought by x-raying not only macroscopically. This should 
be added and the value of specimen x-raying addressed.’ 
 
We thank the reviewer for this comment. We do mention under the section 
entitled ‘Macroscopy and Microscopy’ that ‘access to pre- and post-treatment 
radiological images and reports are invaluable.’ Of course, in difficult cases 
where there has been a very good response to neoadjuvant therapies, it may 
be difficult to macroscopically identify the tumour bed and/or clip(s). In such 
cases, specimen (and, very rarely, specimen slice) X-ray may be of benefit, 
but this is very uncommonly required and therefore not used routinely (as the 
‘MRI coil’ can be seen on slicing the specimen). Indeed, as stated in the 
RCPath guidelines: ‘Often the marker can be detected macroscopically on 
thin slicing of the specimen’. We have, however, added comment that this 
may be helpful in rare cases. 
 
2. ‘Rate of response to dual anti her2 therapy is much higher. Recent reports 
show over 70 percent pCR’. 
We thank the reviewer for this observation but would note that the rates of 
pCR in the neoadjuvant setting of trials in the peer-reviewed published 
literature for non-metastatic breast cancer are generally just over 50% with 
dual agent anti-HER2 therapy (typically peer-reviewed data is available for 
Anonymous list of revisions
trastuzumab and lapatanib; e.g. in NeoALTTO, CALGB-40601/II and in 
NSABP-B41/III). Although presentations have reported higher rates with 
pertuzumab and trastuzumab, we have not been able to source these in peer-
reviewed form. The papers we have referenced in relation to response rates 
with anti-Her2 therapy include a recent meta-analysis, which includes 36 
studies (5768 patients). To our knowledge, this is the most recent large-scale 
review of the available published data. We have not, therefore, amended this 
section, other than to add brief comment about a dual anti-HER2 approach. 
 
3. ‘There are some important references that are worth including and referring 
to.’ 
 
It is unclear if the reviewer if the reviewer here is referring to the RCPath 
pathology guidelines (see below) or if there are additional references that they 
feel we should include. We would be happy to re-edit if these are specified. 
 
4. ‘The authors should highlight what guidelines are available.  
Refer to Pinder et al 2014 paper of neo adjuvant reporting, and Rcpath 
guidelines on this area.’ 
 
We thank the reviewer for drawing our attention to this oversight. We have 
added in the suggested references. 
 
5. ‘Please provide some imaging photos: e.g. clip site, calcifications, imaging 
before and after treatment to be of interest to a radiology readership.  
You may also wish to address relevant radiological issues such as 
calcification in this context ...etc.’  
 
In order to keep to within our expertise (which is not radiological!), and also 
within the word count, we have kept specifically to a brief overview of clinical 
details and concentrated on the histopathological examination and 
assessment; in particular we suspect that a review on standardisation of the 
neoadjuvant therapy radiologically is itself more than a single review article. 
For this reason we have almost completely steered away from issues of 
mammography assessment, peri-treatment radiological assessment (when, 
by MRI or US), re-sampling of radiological calcifications, CT, MRI assessment 
etc etc and we have avoided impudently including any radiological images. If 
the editor feels strongly such images would add to the document we would be 
happy to include these, but would also then need to add significantly to the 
word count to explain why they had been incorporated and the issues of 
controversy? 
 
In response to Reviewer 3’s comments: 
 
‘This is an excellent and timely article on a very important subject 
The article is thorough and presents the information available in a clear and 
logical way which makes it easy for the reader to understand 
well referenced good illustrations which also add to the quality of the paper 
I suggest including a table with more detail on RCB categories.’ 
 
We thank the reviewer for this useful suggestion. A table has been included. 
 
We hope that you find the revised version satisfactory. Please do not hesitate 
to contact me should you require any further information. 
 
 
 
Abstract 
 
Neoadjuvant therapy is increasingly being recognised as a management option for patients 
with primary invasive breast carcinoma; this may take the form of primary endocrine 
treatment or primary chemotherapy. Surgical specimens from women treated with 
neoadjuvant treatments, particularly primary chemotherapy, may cause challenges for the 
histopathologist in handling and interpretation and have, in the past, been sampled, 
evaluated and reported in a non-standardised way. This limits comparison between clinical 
trials and potentially provides clinicians and patients with sub-optimal prognostic 
information. We describe here some of the difficulties faced and the recommendations and 
standards now applied. 
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Abstract  
 
Neoadjuvant therapy is increasingly being recognised as a management option for patients with 
primary invasive breast carcinoma; this may take the form of primary endocrine treatment or 
primary chemotherapy. Surgical specimens from women treated with neoadjuvant treatments, 
particularly primary chemotherapy, may cause challenges for the histopathologist in handling 
and interpretation and have, in the past, been sampled, evaluated and reported in a non-
standardised way. This limits comparison between clinical trials and potentially provides 
clinicians and patients with sub-optimal prognostic information. We describe here some of the 
difficulties faced and the recommendations and standards now applied.  
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Introduction  
 
The management of early breast cancer is constantly changing. As new treatments emerge, 
and as our understanding of the biology of the disease evolves, the use of neoadjuvant 
systemic therapies is increasing. Originally a means to manage patients with inoperable locally 
advanced breast cancer and subsequently to optimise cosmesis in patients with large tumours, 
neoadjuvant systemic therapy is now integral to the treatment of patients with early stage 
disease, even those with smaller lesions suitable for breast conservation at presentation. Large 
clinical trials have shown no differences in survival for patients given systemic therapy pre-, or 
post-, surgery (1-3).  
 
Accurately assessing the efficacy of such treatments in the surgical excision specimen is 
important, not only for understanding which patients will develop recurrent or metastatic disease 
(i.e. prognostication), but also in uncovering mechanisms of resistance that facilitate these poor 
outcomes. However, standardising assessments between laboratories across the globe has 
proven challenging.  
 
Pathological Complete Response  
 
It is well established that patients with tumours that have undergone complete pathological 
response (pCR) have a better prognosis than those that have not. In 2012, an ‘International 
Consensus Conference on the Current Status and Future of Neoadjuvant Systemic Therapy in 
Primary Breast Cancer’ (4) recommended that a complete pathological response (pCR) should 
be histologically determined, and should be defined as an absence of invasive cancer both in 
the breast and axillary lymph nodes. This definition was also recommended by the Residual 
Disease Characterization Working Group of the Breast International Group-North American 
Breast Cancer Group (BIG-NABCG) collaboration in 2015 (5). This definition may seem 
obvious, but others have historically been used by various groups; pCR has previously been 
applied to refer to an absence of disease in breast alone (i.e. with either uninvolved or 
metastatic disease in the axilla) or for cases with no carcinoma in either the breast or the axilla, 
and has even included a range from complete absence of any malignancy in the breast through 
to a definition including cases with minimal residual invasive disease.  
 
The significance of residual disease components in the breast tissue is now clearer. Although 
some have reported a more adverse event-free survival in patients with residual ductal 
carcinoma in situ (DCIS), almost none have identified an effect on overall survival when 
compared to those with no in situ or invasive carcinoma after neoadjuvant chemotherapy (6). 
For this reason, residual DCIS in the breast should be documented, but is considered for 
prognostication purposes as pCR. Conversely, residual ‘pure’ lympho-vascular invasion, even in 
lymph node negative patients, is a poor prognostic feature and should not be considered a 
complete response (7).  
 
Specifically, the definition of pCR that is now recommended includes an absence of disease in 
both breast and axilla. Although typically both axillary and breast foci respond in a similar 
fashion, it is not uncommon to have no residual disease in the breast but metastatic tumour foci 
remaining in the lymph nodes (approximately 5% of cases). Residual disease in the axilla, even 
when the primary breast tumour has completely responded to neoadjuvant chemotherapy 
(NACT), confers a worse prognosis (8).  
 
Selection of patients most suitable for neoadjuvant therapy is an important part of the 
pathologists’ role and their contribution to the multidisciplinary team by providing accurate and 
timely interpretation of core biopsy grade (9) and receptor status (10). The highest pCR rates 
are seen in triple negative breast cancer (TNBC; up to 33.6% following anthracycline based 
chemotherapy) and HER2-positive disease (up to just over 50% after treatment with dual anti-
HER2 targeted therapy) (11-13).  
 
However, it is important to remember that, although high grade invasive cancers are those most 
likely to achieve pCR following NACT, patients with low grade tumours (that typically do not 
respond as markedly to NACT) still have a good outcome, since the tumour was more 
innocuous at baseline. Low grade invasive carcinoma is also likely to be oestrogen receptor 
(ER) positive and neoadjuvant endocrine therapy (NAET) may be a more appropriate option 
compared to grade 3 tumours where pCR is more likely with NACT (irrespective of 
immunohistochemical sub-type) (4, 14). ER-rich invasive lobular carcinoma, for example, 
typically responds relatively poorly to NACT but, in some series, a mean reduction in cancer 
volume of 66% has been reported with NAET (letrozole) (15). Interestingly, progesterone 
receptor (PR) negativity has been shown to be associated with higher rates of pCR to NACT in 
ER-positive HER2-negative breast cancer, but also with a worse long-term outcome in the same 
cohort of patients (16). Thus, frequency of pCR (generally reported at rates of 3-50%) is a 
reflection of thoroughness of histological sampling and examination (see below), clinico- 
pathological characteristics of the tumour and the type of therapy given. Despite best efforts 
however, 60-85% of breast cancer patients typically have residual disease following 
neoadjuvant therapy at present (4). One important challenge, therefore, is to stratify the subset 
of patients who do not have pCR, both for prognostication and, potentially, to evaluate the 
efficacy of newer, ever- emerging therapies.  
 
Macroscopy and Microscopy  
 
It is imperative that pathologists examine and report specimens from patients who have 
received neoadjuvant systemic therapies in a standardised and thorough way (5, 17, 18). These 
specimens in particular require excellent multidisciplinary team working and provision of 
adequate, detailed clinical information on the histology request form. The sites of all of any 
multiple foci of carcinoma present prior to treatment should be examined microscopically and 
these may not be easily apparent in women who have had a good response. Diagrams are 
helpful and access to pre- and post-treatment radiological images and reports are invaluable. 
Markers inserted, even if the patient is advised to undergo mastectomy in some centres, and 
certainly for those undergoing breast-conserving surgery, are sought macroscopically and 
provide the nidus for histological examination. On rare occasions these may be difficult to see 
and then specimen slice x-ray can be performed. Residual tumours may be difficult to palpate 
post-neoadjuvant systemic therapy and are typically softer than pre- treatment. Often, all that is 
seen upon slicing is an ill-defined, pale area of stellate fibrosis. Occasionally, the tumour bed 
may look oedematous, with a glistening cut surface.  
 
Tumours in patients in receipt of NACT more often undergo a scattered pattern of response, 
compared to NAET where a central fibrotic area with a surrounding rim of residual invasive 
disease is common (19). However, not all ER positive tumours are equal, and it has been 
suggested that those with lower levels of ER expression (determined semi-quantitatively by, for 
example, Allred score) respond better to NACT, much like their triple negative counterparts, 
whilst those with high levels of ER expression typically respond to NAET. It is also worth noting 
that the duration of NAET required to induce the best response rates is invariably much longer 
than a course of NACT and that different pathological scoring systems have been used to 
quantify residual disease, precluding precise comparison of patterns of response to these 
different treatments.  
 
Because of the scattered tumour response to NACT often seen, more extensive sampling is 
usually required than for samples from patients who have not received primary systemic 
therapy. Guidance recommends a universal approach to sampling that should not only include 
grossly visible tumour (if present) and the site of marker clip(s), but also the extent of the tumour 
bed/fibrosis and adjacent tissue to encompass the area of involvement by carcinoma before 
treatment (5). The largest cross- section of the pre-treatment area of involvement on slicing 
should be examined microscopically. If available, large ‘mega-blocks’ can be valuable but 
careful targeted and systematic examination is more appropriate than exhaustive sampling; 
some authorities recommend a minimum of one block per cm of pre-treatment tumour size, or at 
least 10 blocks in total, whichever is greater (20).  
 
Microscopically, identifying residual disease can also be difficult, particularly where the 
response has been good (Figure 1). Where pCR has occurred, the tumour bed may consist 
only of fibrosis, which may be loose and oedematous or fibro-elastotic (Figures 2 and 3). 
Typically, no breast epithelial structures are visible in such regions, providing both a useful 
diagnostic clue that this represents tumour bed and confirmation that the correct site has been 
sampled. Inflammation may be present to varying degrees and foamy macrophages may be 
abundant. In other cases, where treatment has been less effective, residual disease is clearly 
apparent, even though NACT may induce morphological changes such that the tumour may not 
resemble that in the original core biopsy, particularly if only a few cancer cells remain (Figure 
3). Specifically, the component of histological grade may change; there may be fewer mitoses 
but a greater degree of tumour cell pleomorphism. Cancer cells may masquerade as 
macrophages and immunohistochemistry evaluation may be required to determine the nature of 
a scanty cell population.  
 
Lymph nodes from patients receiving NACT should be sliced thinly, all embedded and 
haematoxylin and eosin-stained (H&E) sections assessed. Although immunohistochemistry for 
cytokeratin markers highlights cases with fibrosis with very scanty residual metastatic cells not 
seen on H&E stains, such ‘occult’ residual deposits do not seem to have prognostic value (21, 
22) and ‘routine’ immunohistochemistry (rather than for the assessment of suspicious foci seen 
on H&E, which is recommended) is not deemed necessary. Nevertheless, isolated tumour cell 
clusters (ITCs) may be identified in a background of fibrous response to NACT and are not 
regarded as pCR but are interpreted as representing response of larger (micro- or 
macrometastatic) deposits to therapy given.  
 
Assessment of Amount of Residual Disease  
 
It seems inherently logical that the degree to which a tumour has responded to neoadjuvant 
treatment should reflect prognosis; thus patients with pCR have a better outcome than those 
with moderate response, who fare better than those with little tumour reaction to systemic 
therapy. However, how to classify this spectrum has proven elusive. A number of histological 
classification systems have been used to evaluate the degree of response to NACT (23-28), 
whilst few have been described to categorise response to NAET. The systems described have, 
however, been based on different cohorts of patients, with various chemotherapy regimens and 
have applied variable cut- offs for the scoring systems. There are few large-scale comparisons 
of the systems and local preference has largely been the basis for selecting one method over 
another. Nevertheless, conceptually, most of the methods described for classification of degree 
of response to NACT stratify therapeutic response (actually amount of residual disease) 
according to some or all of three criteria: (i) reduction of tumour size, (ii) reduction in cellularity 
of the tumour in the breast and (iii) the reduction in number and size of nodal metastases. Some 
compare the features of the tumour on the prior (pre-treatment) core biopsy, others simply 
assess tumour size and cellularity on the post- treatment histology specimen.  
 
Controversy exists at present as to how best to record the size of the residual tumour post-
NACT, regardless of location (i.e. breast or lymph node). The latest American Joint Committee 
on Cancer (AJCC) (TNM8) now recommend inclusion of only the largest contiguous area of 
tumour (tumour cells touching each other). In the breast, this poses a problem when the tumour 
responds with a scattered pattern, since individual foci may be separated from each other by 
intervening fibrosis. Thus, measuring the size of one focus alone would significantly 
underestimate the total volume of residual tumour. Similarly, the AJCC advocates a similar 
approach to lymph node deposits such that only the largest area in which cells are touching one 
another is measured. Clearly, for those nodes in which only disparate isolated tumour cell 
clusters (ITC) remain, this is likely once again to underestimate the residual metastatic volume; 
in fact, such measurements would result in nodes bearing ITCs being classified as negative, 
when in fact, in the post-NACT setting, they are considered positive (i.e. not pCR). Indeed, there 
are no studies showing an association between this method of quantification and survival 
outcome at present. For this reason, we continue to measure the overall size of adjacent islands 
of metastatic disease that remains in the lymph nodes after NACT, unless clearly widely 
separated by normal nodal structure (i.e. not within a fibrous background that is in essence 
equivalent to the metastatic tumour bed) and to assess the overall extent of scattered foci of 
disease in the breast tissue.  
 
For treatment naïve disease, the size of the nodal deposit is proportional to patient outcome, i.e. 
the smaller the metastasis, the less the effect on their prognosis. Even the way in which 
pathologists quantify and report disease in the axilla (i.e. isolated tumour cell clusters versus 
micro- and macro- metastasis) reflects the recognition that metastatic tumour volume is 
important (hence the afore- mentioned objections to the current AJCC recommendations). 
Whilst this holds true in the context of residual disease after NACT, it is also clear that response 
of the nodal metastasis significantly improves outcome; regression or reduction of nodal tumour 
volume improves disease-free survival and reduces risk of relapse (29). Patients with nodes 
showing features of prior node involvement, but with no residual tumour cells in the nodes have 
an intermediate prognosis between those with residual metastasis and those with normal 
negative lymph nodes (5, 28). Post NACT, pathologists should thus record not only the number 
of lymph nodes remaining positive, but whether or not any treatment-related changes (e.g. 
fibrosis) are present, the latter whether or not tumour cells are identified.  
 
Rajan et al demonstrated that some tumours maintain a similar overall size after NACT to the 
pre- treatment core, but dramatically decrease in cellularity (30). This group went on to suggest 
that the product of these two measurements (i.e. overall remaining tumour size and tumour 
cellularity) was more clinically relevant in determining response than tumour size alone and to 
develop the Residual Cancer Burden (RCB) scoring system (28). This system is recommended 
by many as the ‘preferred method for more detailed quantification of residual disease’ (5). The 
major advantage of the RCB score is that it combines the extent of remaining tumour in the 
breast and its cellularity and size of nodal deposits in such a manner that it allows for both a 
continuous (numerical) and categorical output and has been shown to be associated 
significantly with long-term survival outcome. Mathematically, equal weight is given to the 
presence of residual disease in both the breast and the lymph nodes. The score is ultimately an 
assessment of overall tumour volume, with small changes in any of the parameters causing a 
change in the continuous score, and larger changes potentially causing a change in the RCB 
category (0 to III; Table 1). The lower the score, the lower the risk of distant recurrence. The 
score has been shown to be highly reproducible, even in the ‘routine’ diagnostic setting (31, 32). 
Other systems, such as the 6 grades of the Japanese Breast Cancer Society, have also been 
shown to be reproducible (33) but are nevertheless not widely utilised globally.  
 
One of the limitations of all present systems for histological classification of degree of response 
to neoadjuvant systemic therapies is that they do not necessarily reflect the intrinsic biology of 
the tumour itself. There is scope, therefore, to refine this stratification method by incorporating 
biomarkers into the assessment. Indeed there is some evidence that inclusion of the 
proliferation marker, Ki67, to the RCB adds value and that a prognostic index incorporating 
RCB, post-treatment Ki67, grade and ER may provide even more prognostic information (34). 
However, in its present form the RCB has been shown to provide prognostic information across 
the sub-types of invasive breast carcinoma (triple negative, HER2 positive and hormone 
receptor positive)(35) with estimates of 10- year relapse-free survival rates in the four RCB 
classes (RCB 0 (pCR), RCB I, RCB II, and RCB III) of 86%, 81%, 55% and 23% for triple 
negative, 83%, 97%, 74% and 52% for hormone receptor positive, and 95%, 77%, 47% and 
21% for those patients with HER2 positive disease.  
 
Other biomarkers are currently under investigation and are reported as potentially important as 
both predictors of likelihood of response to, and of prognostic value after, NACT. Whilst tumour- 
infiltrating lymphocytes (TILs) are reported to be of prognostic value in patients with triple 
negative breast cancer who have received NACT (as a marker of good prognosis, even in those 
patients with a large residual tumour burden) (36), further work is required on standardisation of 
this biomarker. Importantly, the infiltrating immune cells are likely to be functionally (and 
prognostically) variable depending on their location, nature of the lymphoid cells and the sub-
type of the breast cancer. For example, in some series it is reported that lymphocyte 
predominant HER2 positive cancers are more likely to achieve pCR (37), whilst in other studies 
the levels of TILs in pre-treatment specimens has not been found to be significantly associated 
with response to NACT in this sub-type (38). Systematic review and meta-analyses indicates 
that TILs predict higher pCR rates in triple negative (OR = 2.49, 95% confidence intervals (CI) 
1.61-3.83) and HER2 positive (OR = 5.05, 95% CI 2.86-8.92) breast cancers, but not in ER 
positive (OR = 6.21, 95%CI 0.86-45.15) disease (39); the situation is clearly complicated and 
not yet appropriate for routine reporting outwith the research setting.  
 
What may, therefore, be more immediately relevant to pathologists is achieving consensus on 
the significance and value of ‘simple’ tumour biomarkers. Although some experts maintain that 
reassessment of tumour receptors (e.g. ER, PR and HER2) on post-NACT residual tumour is 
essential (40), this is not universally recommended. It is clear that whilst some standardisation 
of handling and reporting specimens from patients receiving neoadjuvant treatments have been 
achieved, this is a continually evolving field and additional work is required.  
 
Imaging Biomarkers  
 
One ongoing area of research focus is the comparison of the results of various imaging 
modalities for assessment of treatment response (both during and after neoadjuvant systemic 
therapy) with pathological findings. One recent meta-analysis, which included 10 studies (six 
prospective and four retrospective), showed MRI to be more sensitive than FDG-PET/CT in 
evaluating response post-NACT (0.88 versus 0.57) but FDG-PET/CT to be more specific than 
MRI in evaluating response during therapy (0.69 versus 0.42) (37). The EUSOMA working 
group has for many years recommended MRI for the assessment of residual disease post-
NACT (41) but the evidence on whether this is accurate across all sub-types of invasive cancer 
is less clear (42-45).  
 
Additional imaging research is required to optimise methods for accurately categorising the 
amount of residual disease during neoadjuvant systemic treatment. Whilst at the end of 
treatment the correlation between the MRI and pathological measurements of residual tumour 
(i.e. in the excised specimen) ranges from 0.65 to 0.98, in some series only ~70% of MRI size 
evaluations were accurate (46). Series correlating standardised (end of treatment) RCB scores 
with imaging assessments will provide valuable data on the accuracy of the latter; this is likely to 
be increasingly important for the accurate identification of women with significant residual 
tumour in planned clinical trials of further pre-operative systemic treatment. Clearly imaging 
biomarker studies of this type require correlation with standardised pathology categorisation and 
have been historically therefore been problematic, because of the lack of robust 
histopathological data.  
 
Conclusion  
 
The increased use of neoadjuvant systemic therapies for patients with invasive breast cancer, 
and the greater proportion of patients achieving good responses to more personalised 
treatments, has highlighted the need for accurate, standardised pathological assessment and 
classification. Recent guidelines have gone some way to set standards and, at a tissue level, 
our understanding of patterns of tumours response has increased. Nevertheless, work still 
needs to be done and there is the potential to refine and improve current systems. Future 
research comparing histological and imaging biomarkers of response to neoadjuvant systemic 
therapies will also be crucial to improving patient management, for example for future trials 
omitting surgery for patients with complete response to NACT or, conversely, identifying those 
with limited tumour response who may benefit from additional systemic therapy prior to surgery.  
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Table 1 Residual Cancer Burden Categories 
 Complete 
Pathological 
Response 
(pCR) 
RCB I RCB II RCB 3 
Amount of residual tumour present 
(Calculation of: tumour in mm in two 
dimensions; % cellularity of the 
carcinoma; % of DCIS; size of largest 
nodal metastasis; number of nodes with 
metastasis) 
None Minimal Moderate Extensive 
Numerical cut -off 0 <1.36 1.36-3.28 >3.28 
Risk of distant recurrence  Low Intermediate High 
 
Figure Legends  
 
Figure 1: Low power magnification (haematoxylin and eosin stained section) of a portion of 
wide local excision post-neoadjuvant chemotherapy showing an area of fibrosis (lower portion of 
tissue) representing the tumour bed (site of tumour before treatment). The solid arrow shows 
the site at which a marker coil had previously been removed in the laboratory prior to sampling 
and processing (shown at higher magnification in Figure 2) and the dashed arrow shows the 
site of small clusters of residual invasive carcinoma (not visible at this power but shown at a 
higher magnification in Figure 3).  
 
Figure 2: Confirmation of the presence of tumour bed around an inserted marker. The tumour 
bed is seen as fibrous stroma. This is focally loose and oedematous but elsewhere is more 
hyalinised. The site of marker is seen as a gap in the tissue (bottom left). No residual cancer 
cells are seen in this area.  
 
Figure 3: Residual invasive breast cancer cells and stromal calcification post-neoadjuvant 
chemotherapy. Small clusters of residual invasive cancer cells (arrows) are seen, and an area 
of microcalcification in the stroma adjacent to an uninvolved residual duct.  
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